Table 2. Oligonucleotides used.

Name	Sequence (5΄-3΄)a	Coordinatesb
FP-rnaII	GCACTCCAAGCGTTTCAAGTTTCAGCTC	946–919
IR1+8	ACTTTATGAATATAAAGTATAGTGTG	3570–3595
PctII	TCTTTAGCCATAAAGTATAATATA	863–840
1SacI	ATAAGAGCTCATGCGAGAGTAGGGAACTGC	N.A.
2/C3	AAAGACACACGAGGCTCGCCCGGGGATCCTCTA	N.A.
4SacI	attagagctCGACCAAAACCATAAAACCTT	3541–3521
C2/3	ccccgggcgagcCTCGTGTGTCTTTCGGTAATC	3683–3703
PE-tet	GAGGGCAGACGTAGTTTATAGG	1717–1696
PE-mobM	CCCTCCTTAAGACTTGTCTTTCG	3725–3703
PE-cop-rep	CCGATTCACTTAATGTTATCGTCA	691–668
PE-rnaII	TGCTGGCAGGCACTGGC	802–818
M13-forward	GTAAAACGACGGCCAGT	N.A.
RNAII-F	AGTCGCTTGGAATTCATTCAGGATA	916–892
RNAII-R	CAGGCACTGGCTGCAGTCAAACATT	808–832
ΔORI-F	AGTATAGTGTGTTAGAATTCACATGGAAGTTATA	3585–3618
ΔORI-R	CAGACGAGCCGCTGCAGTCTATTGCT	3690–3665

^aBase changes that generate restriction sites (in bold) are underlined. Tail sequences are indicated in lower case letters.

^bCoordinates are given with respect to pMV158 sequence (GenBank acc. no. NC_010096), except for 1SacI and 2/C3 (N.A., do not apply).